CVS Health (CVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual Meeting scheduled for May 14, 2026, at 8:00 A.M. ET, to be held virtually for shareholder participation.
Shareholders are encouraged to vote in advance or during the virtual meeting, with materials available online or by request.
Voting matters and shareholder proposals
Election of 13 directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of the appointment of the independent registered public accounting firm for 2026 is proposed.
Advisory vote on executive compensation (Say on Pay) and approval of the 2026 Incentive Compensation Plan are included.
Shareholder proposal to reduce the threshold for the right to act by written consent is presented, with the board recommending against it.
Board of directors and corporate governance
Board recommends all director nominees for election, reflecting ongoing governance and oversight priorities.
Latest events from CVS Health
- Targeting mid-teens EPS CAGR through 2028 and launching an AI-native engagement platform in 2026.CVS
Investor Day 20259 Jul 2026 - 2025 guidance targets adjusted EPS of $5.75–$6.00 and revenue of at least $385.9B.CVS
Q4 20248 Jul 2026 - Revenue up 8.4% year-over-year; GAAP EPS fell on litigation, adjusted EPS steady.CVS
Q2 20258 Jul 2026 - All management proposals passed; shareholder proposal on written consent threshold failed.CVS
AGM 202620 May 2026 - Q1 2026 revenue up 6.2% to $100.4B; EPS and guidance raised on strong Health Care Benefits.CVS
Q1 20267 May 2026 - Proxy covers director elections, pay alignment, new incentive plan, and Board-opposed proposal.CVS
Proxy filing3 Apr 2026 - Integrated pharmacy, PBM, and digital platforms drive consumer-focused, affordable healthcare.CVS
Leerink Global Healthcare Conference 20269 Mar 2026 - 2025 revenue and EPS exceeded expectations, but earnings hit by goodwill and litigation charges.CVS
Q4 202510 Feb 2026 - Q2 revenue up 2.6% to $91.2B, but EPS and guidance cut amid Health Care Benefits headwinds.CVS
Q2 20242 Feb 2026